Isofol Medical – executive interview

Isofol Medical – executive interview

In this interview with Petter Segelman Lindqvist, CEO of Isofol Medical, we discuss the company’s lead clinical programme, the mechanism of action of arfolitixorin and the recently announced rights issue. We also highlight the key catalysts that investors should watch out for in the year ahead.

Isofol Medical is a Sweden-based clinical-stage biotechnology company dedicated to improving prognoses for patients with severe forms of cancer. The company’s lead clinical candidate, arfolitixorin, is designed to increase the effect of standard treatments for several forms of solid tumours, with an initial focus on colorectal cancer. A Phase Ib/II trial is currently underway, following first patient dosing in April 2025.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.